1. India Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Tyche Industries Limited

Tyche Industries Limited

TYCHE.BO
Tyche Industries LimitedIN flagBombay Stock Exchange
126.35
INR
+0.80
- -
1.30BMarket Cap
Tyche Industries Limited
TYCHE.BO
(Bombay Stock Exchange)

Recent

price

126.35

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
45.42
49.91
76.69
101.98
62.43
52.86
41.73
50.36
52.79
71.94
76.37
60.78
73.58
67.85
64.33
- -
51.44
Revenue per Share
2.41
2.87
5.96
5.4
1.89
2.41
3.02
5.72
6.97
17.14
19.51
9.11
13.83
11.95
12.19
- -
6.65
Basic EPS, GAAP
-5.69
0.61
-3.14
2.24
1.24
10.45
11.07
3.53
2.51
14.53
12.64
3.39
4.57
4.38
7.68
- -
- -
Free Cash Flow per Basic Share
0.57
0.58
0.5
0.5
0.6
0.6
0.5
0.5
- -
0.5
1
1
1.5
2
2.52
- -
- -
Dividend per Share
27.76
30.23
34.08
38.12
38.03
39.5
41.53
46.21
52.89
69.1
87.3
95
107.04
116.66
126.84
- -
9.83
Book Value per Share
30.59
33.43
37.77
42.6
42.8
44.56
46.89
51.85
58.82
75.32
93.67
101.73
113.96
123.7
134.31
- -
134.73
Tangible Book Value per Share
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
- -
10
Basic Weighted Avg Shares
457
494
785
1,043
639
541
426
516
541
737
782
623
754
695
655
536
536
Sales/Revenue/Turnover
7.92
10.75
11.91
8.89
5.93
2.14
9.98
13.92
13.84
27.44
30.87
15.9
19.36
15.65
14.21
0.45
0.45
Operating Margin (%)
8
9
11
14
33
18
19
18
18
17
17
18
18
19
20
20
20
Depreciation Expense
24
28
61
55
19
25
31
59
71
176
200
93
142
122
124
69
69
Net Income, GAAP
28.22
30.6
32.8
32.32
32.53
3.34
48.05
33.87
27.42
24.72
25.25
26.15
25.74
26.38
25.77
26.7
26.78
Effective Tax Rate (%)
5.31
5.75
7.77
5.29
3.02
4.56
7.23
11.36
13.21
23.82
25.54
14.99
18.8
17.61
18.95
12.93
12.92
Profit Margin (%)
100
127
133
133
149
167
220
344
421
603
785
882
959
1,064
1,113
1,014
1,014
Working Capital
- -
10
10
10
- -
- -
- -
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
308
331
386
436
438
456
479
531
603
772
960
1,042
1,168
1,267
1,367
1,405
1,405
Total Equity
7.43
9.04
14.11
12.26
4.8
2.05
4.24
9.4
9.57
22.14
20.86
7.31
9.78
6.54
5.21
0.13
0.13
Return on Invested Capital (%)
8.78
9.9
16.4
13.27
5.45
5.55
6.67
13.05
14.06
28.09
24.95
9.99
13.69
10.68
9.98
9.96
9.95
Return on Capital (%)
8.95
9.82
18.82
14.95
4.96
6.22
7.44
13.06
14.08
28.1
24.94
9.99
13.69
10.68
9.98
9.96
9.95
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
10
- -
10
Market Capitalization
1,405
1,164
1,040

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
666
- -
1,079
Cash, Cash Equivalents & STI
271
- -
753
Accounts Receivable, Net
170
- -
195
Inventories
182
- -
99
Total Current Liabilities
126
- -
66
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.16%
7.96%
2.76%
Free Cash Flow
28.94%
-17.2%
-117.94%
Net Income, GAAP
23.89%
-11.56%
-44.09%
Sales/Revenue/Turnover
1.61%
-6.21%
-18.08%
Total Cash Common Dividend
- -
- -
20%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
171
160
222
142
695
2025
155
205
178
124
655
2026
127
142
106
162
536

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.65
3.06
4.18
- -
11.95
2025
2.66
3.9
4.63
1
12.19
2026
2.37
1.49
1.78
1.05
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
2
2025
- -
- -
- -
- -
2.52
2026
- -
- -
- -
- -
- -
Similar Companies
Noveris Health Sciences Inc. (MYCOF)
China BCT Pharmacy Group, Inc. (CNBI)
Targeted Medical Pharma, Inc. (TRGM)
Kimia Biosciences Ltd. (KIMIABL.BO)
Welcia Holdings Co., Ltd. (3141.T)
Core One Labs Inc. (CLABF)
Business
Tyche Industries Limited manufactures active pharmaceutical ingredients, advanced and chiral intermediates, and nutraceuticals in India for export primarily to the United States and Europe; the company offers contract development and manufacturing organization services, analytical development, and custom synthesis or toll manufacturing of fine and specialty chemicals. Incorporated in 1998 and headquartered in Hyderabad, Telangana, with manufacturing facilities in Kakinada, Andhra Pradesh, it maintains good manufacturing practice standards and targets pharmaceutical and biotech customers globally. In 2025, the company successfully completed a GMP inspection by Brazil's ANVISA regulatory agency at its Kakinada facility, announced leadership changes including the appointment of Sandeep Gokaraju as Chairman and Managing Director replacing G Ganesh Kumar, and initiated a 30% dividend payout for FY 2024-25.